Johnson & Johnson

Addressing critical public health challenges requires bold leadership and novel approaches.  Despite tremendous progress in medical science and technology during the last decades, significant health gaps remain for many people around the globe.

Emerging new global challenges will require collective effort and partnerships to deliver solutions. Johnson & Johnson Global Public Health (GPH) is the first fully dedicated organization within a healthcare company focused on combining innovative R&D, novel access programs, country-based operations and advocacy. GPH aims to ensure that treatments and technologies are available, affordable and accessible for the world’s most under served populations as we work to realize a world without disease.

Our GPH strategy tackles some of the world’s most pressing health challenges, targeting transformational health outcomes for individuals and communities. This includes aspirations to eliminate human immunodeficiency virus (HIV) and tuberculosis (TB), and reduce the burden of neglected tropical diseases and non-communicable diseases alongside addressing critical issues such as mental health and the threat of drug resistance and global pandemics.

As a global healthcare leader, Johnson & Johnson is at the forefront of addressing the world’s most intractable diseases. In 2018, we maintained our planned actions to reduce the burden of prominent diseases and are on track against our published targets, advancing better health for adults and children around the world.

Read more in our 2018 Health for Humanity report which highlights how we act and innovate with bold leadership and purpose to drive better health for all by eradicating and preventing disease, re-imagining how care is delivered and aiming to put good health within reach of everyone, everywhere.